(Q38111454)

29 August 2017

title

Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition (English)

1 reference

29 August 2017

Luis M Ruilope

3

0 references

author name string

Julian Segura

series ordinal

1

1 reference

29 August 2017

Jorge Salazar

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

4 June 2013

1 reference

Expert Opinion on Investigational Drugs

29 August 2017

published in

1 reference

29 August 2017

volume

22

1 reference

29 August 2017

issue

7

1 reference

29 August 2017

page(s)

915-925

1 reference

Global burden of blood-pressure-related disease, 2001.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Current challenges in the clinical management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Biology of natriuretic peptides and their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Molecular biology of the natriuretic peptide system: implications for physiology and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Vasopeptidase inhibition: a double-edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

AT2 receptor agonists: hypertension and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Novel roles of nuclear angiotensin receptors and signaling mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Effect of valsartan on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Dual-acting angiotensin receptor-neprilysin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Annual rates of admission and seasonal variations in hospitalizations for heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Prognostic factors and long-term survival after initial diagnosis of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Combined neutral endopeptidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.797962

10.1517/13543784.2013.797962

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference